For the quarter ending 2025-09-30, FDMT made $90,000 in revenue. -$56,876,000 in net income. Net profit margin of -63195.56%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Collaboration and license revenue | 90,000 | 15,000 | 14,000 | 11,333.333 |
| Research and development | 49,438,000 | 47,951,000 | 40,699,000 | 34,271,666.667 |
| General and administrative | 11,837,000 | 11,520,000 | 12,936,000 | 11,309,333.333 |
| Total operating expenses | 61,275,000 | 59,471,000 | 53,635,000 | 45,581,000 |
| Loss from operations | -61,185,000 | -59,456,000 | -53,621,000 | -45,569,666.667 |
| Interest income | 4,330,000 | 4,859,000 | 5,582,000 | 6,586,666.667 |
| Other income (expense), net | -21,000 | -61,000 | 67,000 | -25,333.333 |
| Total other income, net | 4,309,000 | 4,798,000 | 5,649,000 | 6,561,333.333 |
| Net loss | -56,876,000 | -54,658,000 | -47,972,000 | -39,008,333.333 |
| Earnings per share, basic | -1.01 | -0.98 | -0.86 | -0.73 |
| Earnings per share, diluted | -1.01 | -0.98 | -0.86 | -0.73 |
| Weighted average number of shares outstanding, basic | 56,126,330 | 55,927,091 | 55,744,047 | -536,911.667 |
| Weighted average number of shares outstanding, diluted | 56,126,330 | 55,927,091 | 55,744,047 | -536,911.667 |
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)